文献速递消化道肿瘤与早癌消化内镜

病理分期T1b食管癌内镜黏膜下剥离术的多中心结局研究

Outcomes for endoscopic submucosal dissection of pathologically staged T1b esophageal cancer: a multicenter study.
PubMed 文献 · Gastrointest Endosc · 2022-02-22

该多中心队列纳入美国6家和巴西1家学术中心共66例病理分期T1b食管癌行ESD的患者,整块切除率92.4%(61/66),R0切除率54.5%(36/66),R1切除与复发风险升高相关(HR 6.25,95%CI 1.29-30.36,P=.023)。

要点

  • ESD术前EUS分期T1b食管癌准确性差,应考虑分期性ESD。
  • T1b食管癌ESD的R0切除率低(54.5%)。
  • R1切除与复发疾病风险升高相关(HR 6.25)。

核心结论

  • T1b食管癌EUS分期准确性差,应考虑分期性ESD。
  • T1b食管癌ESD的R0切除率低,R1切除与复发疾病相关。
  • 非治愈性ESD切除后无法手术的T1b食管癌患者应密切监测,因25%出现复发疾病。

研究设计与样本

  • 多中心队列研究,纳入美国6家和巴西1家学术三级转诊中心行ESD的病理分期T1b食管癌患者66例。
  • 分析人口学、操作和組織病理学特征及随访数据,采用时间-事件分析评估复发率。

主要发现

  • 66例病理分期T1b食管癌患者中,54例有术前EUS分期,其中Tis/T1a 27例(50%)、T1b 27例(50%)。
  • 整块切除率92.4%(61/66),R0切除率54.5%(36/66)。
  • 66例中49例(74.2%)切除后未立即手术而进入监测。
  • 符合治愈性切除标准的10例患者在13个月(范围3-18.5)随访期内未见复发。
  • 39例非治愈性切除患者中10例(25.6%)有残留/复发疾病,其中局部复发5例(12.8%)、转移性复发5例(12.8%)。

关键数值与推荐

  • 单因素分析显示R1切除与复发疾病风险升高相关(风险比6.25,95%置信区间1.29-30.36,P=.023)。

临床怎么用

  • 作者认为T1b食管癌EUS分期准确性差,应考虑分期性ESD。
  • 作者认为非治愈性ESD切除T1b食管癌后无法手术的患者应密切监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The outcomes of endoscopic submucosal dissection (ESD) for T1b esophageal cancer (EC) and its recurrence rates remain unclear in the West. Using a multicenter cohort, we evaluated technical outcomes and recurrence rates of ESD in the treatment of pathologically staged T1b EC. METHODS: We included patients who underwent ESD of T1b EC at 7 academic tertiary referral centers in the United States (n = 6) and Brazil (n = 1). We analyzed demographic, procedural, and histopathologic characteristics and follow-up data. Time-to-event analysis was performed to evaluate recurrence rates. RESULTS: Sixty-six patients with pathologically staged T1b EC after ESD were included in the study. A preprocedure staging EUS was available in 54 patients and was Tis/T1a in 27 patients (50%) and T1b in 27 patients (50%). En-bloc resection rate was 92.4% (61/66) and R0 resection rate was 54.5% (36/66). Forty-nine of 66 patients (74.2%) did not undergo surgery immediately after resection and went on to surveillance. Ten patients had ESD resection within the curative criteria, and no recurrences were seen in a 13-month (range, 3-18.5) follow-up period in these patients. Ten of 39 patients (25.6%) with noncurative resections had residual/recurrent disease. Of the 10 patients with noncurative resection, local recurrence alone was seen in 5 patients (12.8%) and metastatic recurrence in 5 patients (12.8%). On univariate analysis, R1 resection had a higher risk of recurrent disease (hazard ratio, 6.25; 95% confidence interval, 1.29-30.36; P = .023). CONCLUSIONS: EUS staging of T1b EC has poor accuracy, and a staging ESD should be considered in these patients. ESD R0 resection rates were low in T1b EC, and R1 resection was associated with recurrent disease. Patients with noncurative ESD resection of T1b EC who cannot undergo surgery should be surveyed closely, because recurrent disease was seen in 25% of these patients.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Joseph A, Draganov PV, Maluf-Filho F, et al. Outcomes for endoscopic submucosal dissection of pathologically staged T1b esophageal cancer: a multicenter study. Gastrointest Endosc. 2022. PMID: 35217020. doi:10.1016/j.gie.2022.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。